PL335934A1 - Solvent system of increased penetration into pharmaceutical compounds - Google Patents
Solvent system of increased penetration into pharmaceutical compoundsInfo
- Publication number
- PL335934A1 PL335934A1 PL98335934A PL33593498A PL335934A1 PL 335934 A1 PL335934 A1 PL 335934A1 PL 98335934 A PL98335934 A PL 98335934A PL 33593498 A PL33593498 A PL 33593498A PL 335934 A1 PL335934 A1 PL 335934A1
- Authority
- PL
- Poland
- Prior art keywords
- solvent system
- pharmaceutical compounds
- increased penetration
- penetration
- increased
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000035515 penetration Effects 0.000 title 1
- 239000002904 solvent Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82909197A | 1997-03-31 | 1997-03-31 | |
PCT/US1998/004033 WO1998043673A1 (en) | 1997-03-31 | 1998-03-03 | Solvent system for enhanced penetration of pharmaceutical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PL335934A1 true PL335934A1 (en) | 2000-05-22 |
Family
ID=25253504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL98335934A PL335934A1 (en) | 1997-03-31 | 1998-03-03 | Solvent system of increased penetration into pharmaceutical compounds |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0971746A1 (es) |
JP (1) | JP2001518879A (es) |
KR (1) | KR19980081207A (es) |
CN (1) | CN1252003A (es) |
AR (1) | AR012217A1 (es) |
AU (1) | AU6677698A (es) |
BR (1) | BR9811458A (es) |
CA (1) | CA2285368A1 (es) |
CO (1) | CO5050328A1 (es) |
HU (1) | HUP0001739A3 (es) |
IL (1) | IL132096A0 (es) |
PL (1) | PL335934A1 (es) |
WO (1) | WO1998043673A1 (es) |
ZA (1) | ZA982662B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2232855C (en) * | 1997-04-10 | 2007-10-09 | Roche Consumer Health (Worldwide) Sa | Pharmaceutical formulation |
AU5146600A (en) * | 1999-05-27 | 2000-12-18 | Procter & Gamble Company, The | Topical compositions providing improved treatment of skin or scalp fungal infections |
GB0103046D0 (en) | 2001-02-07 | 2001-03-21 | Novartis Ag | Organic Compounds |
IL142037A0 (en) * | 2001-03-15 | 2002-03-10 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug |
MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
JP4784051B2 (ja) * | 2003-07-03 | 2011-09-28 | 大正製薬株式会社 | 容器への吸着を防止した外用抗真菌組成物 |
JP5435836B2 (ja) * | 2003-07-03 | 2014-03-05 | 大正製薬株式会社 | 外用抗真菌剤組成物 |
DE102005059742A1 (de) | 2005-12-13 | 2007-06-14 | Beiersdorf Ag | Transparentes Sonnenschutzmittel |
US20080032994A1 (en) | 2006-08-03 | 2008-02-07 | Marcel Borgers | Modified azole compounds as antifungal and antibacterial agents |
SI2079441T1 (sl) * | 2007-07-25 | 2010-12-31 | Ixodes Gmbh | Topični antibiotične sestavek za preprečevanje lymske bolezni |
PL2191825T3 (pl) | 2007-08-27 | 2016-11-30 | Środek przeciwko grzybiczemu zapaleniu skóry | |
US20090175810A1 (en) | 2008-01-03 | 2009-07-09 | Gareth Winckle | Compositions and methods for treating diseases of the nail |
US8039494B1 (en) | 2010-07-08 | 2011-10-18 | Dow Pharmaceutical Sciences, Inc. | Compositions and methods for treating diseases of the nail |
US9839611B2 (en) * | 2013-09-10 | 2017-12-12 | Insys Development Company, Inc. | Sublingual buprenorphine spray |
MY179756A (en) | 2013-10-03 | 2020-11-12 | Dow Pharmaceutical Sciences | Stabilized efinaconazole formulations |
CN112999223A (zh) | 2013-11-22 | 2021-06-22 | 博世健康爱尔兰有限公司 | 抗感染的方法、组合物和装置 |
CN115745757B (zh) * | 2022-11-07 | 2024-04-26 | 中国人民解放军军事科学院军事医学研究院 | 一种液态多甘醇柱芳烃衍生物的合成及对经皮药效分子缓释的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2051998T3 (es) * | 1988-02-29 | 1994-07-01 | Pfizer | Composiciones aumentadoras del flujo transdermal. |
GB8827822D0 (en) * | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
CN1106259A (zh) * | 1994-02-05 | 1995-08-09 | 日东制药株式会社 | 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂 |
-
1998
- 1998-03-03 HU HU0001739A patent/HUP0001739A3/hu unknown
- 1998-03-03 AU AU66776/98A patent/AU6677698A/en not_active Abandoned
- 1998-03-03 PL PL98335934A patent/PL335934A1/xx unknown
- 1998-03-03 EP EP98908843A patent/EP0971746A1/en not_active Withdrawn
- 1998-03-03 WO PCT/US1998/004033 patent/WO1998043673A1/en not_active Application Discontinuation
- 1998-03-03 JP JP54163598A patent/JP2001518879A/ja active Pending
- 1998-03-03 IL IL13209698A patent/IL132096A0/xx unknown
- 1998-03-03 CN CN98803908A patent/CN1252003A/zh active Pending
- 1998-03-03 BR BR9811458-1A patent/BR9811458A/pt not_active Application Discontinuation
- 1998-03-03 CA CA002285368A patent/CA2285368A1/en not_active Abandoned
- 1998-03-30 ZA ZA9802662A patent/ZA982662B/xx unknown
- 1998-03-31 AR ARP980101461A patent/AR012217A1/es unknown
- 1998-03-31 KR KR1019980012493A patent/KR19980081207A/ko not_active Application Discontinuation
- 1998-03-31 CO CO98017937A patent/CO5050328A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2285368A1 (en) | 1998-10-08 |
CN1252003A (zh) | 2000-05-03 |
HUP0001739A3 (en) | 2001-04-28 |
IL132096A0 (en) | 2001-03-19 |
JP2001518879A (ja) | 2001-10-16 |
WO1998043673A1 (en) | 1998-10-08 |
CO5050328A1 (es) | 2001-06-27 |
ZA982662B (en) | 1999-09-30 |
AR012217A1 (es) | 2000-09-27 |
AU6677698A (en) | 1998-10-22 |
HUP0001739A2 (hu) | 2000-12-28 |
BR9811458A (pt) | 2000-09-19 |
KR19980081207A (ko) | 1998-11-25 |
EP0971746A1 (en) | 2000-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9602080D0 (en) | Pharmaceutical compounds | |
PT892640E (pt) | Composicoes farmaceuticas de micofenolato entericamente revestidas | |
EG24044A (en) | pharmaceutical formulation of omeprazole | |
GB9700504D0 (en) | Pharmaceutical compounds | |
PL335934A1 (en) | Solvent system of increased penetration into pharmaceutical compounds | |
EG22250A (en) | Novel pharmaceutical compound | |
EP0941039A4 (en) | TRANSDERMAL ADMINISTRATION OF 7alpha-METHYL-19-NORTESTOSTERONE ("MENT") | |
GB9722600D0 (en) | Pharmaceutical compositon | |
EP1003495A4 (en) | PHARMACEUTICAL COMPOUNDS | |
GB9609976D0 (en) | Pharmaceutical compounds | |
GB9716244D0 (en) | Pharmaceutical compounds | |
GB9621789D0 (en) | Pharmaceutical compounds | |
AU4330097A (en) | Pharmaceutical compounds | |
GB9700737D0 (en) | Administration of drugs | |
IL126050A0 (en) | Sustained-release pharmaceutical formulations containing mizolastin | |
EP0923564A4 (en) | PHARMACEUTICAL COMPOUNDS | |
ZA979329B (en) | Pharmaceutical compounds | |
GB9700895D0 (en) | Pharmaceutical compounds | |
HUP9904328A3 (en) | Solvent extraction of 3-hydroxymethylcephalosporins | |
GB9626151D0 (en) | Pharmaceutical compounds | |
GB2360470B (en) | Solvent mixture | |
HU9700442D0 (en) | Compounds of pharmaceutical activity | |
ZA987535B (en) | Pharmaceutical compounds | |
GB9705400D0 (en) | Pharmaceutical compounds | |
GB9706302D0 (en) | Pharmaceutical compounds |